

**Oklahoma Health Care Authority
Drug Utilization Review Board**
(DUR Board)
Meeting – June 8, 2011 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. May 11, 2011 DUR Minutes – Vote
 - B. May 12, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review Response for February 2011
 - B. Medication Coverage Activity Audit for May 2011
 - C. Pharmacy Help Desk Activity Audit for May 2011

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Topical Corticosteroid Products – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Le, Dr. Muchmore, Chairman

6. **Action Item – Votes to Prior Authorize Miscellaneous Products – See Appendix D.**
 - A. Vote to Prior Authorize Practitioner Administered Drugs, Including Benlysta[®]
 - B. Vote to Prior Authorize Adcirca[®]
 - C. Vote to Prior Authorize Colcrys[®] and Uloric[®]
 - D. Vote to Prior Authorize Miscellaneous Bladder Agents
 - E. Vote to Prior Authorize Neudexta[™]
 - F. Vote to Prior Authorize Testosterone Replacement Products

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **Utilization Review and 60 Day Notice to Prior Authorize Diabetes Medications – See Appendix E.**
 - A. Utilization Overview
 - B. Current Clinical Guidelines
 - C. Market Update
 - D. COP Recommendations
 - E. Economic Impact

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Anxiolytic Prior Authorization Category – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Analysis of New Prior Authorization Criteria
 - D. COP Recommendations

Items to be presented by Dr. Phung, Dr. Le, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Anti-Emetics and 30 Day Notice to Prior Authorize Zuplenz™ – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. New Product Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

10. **Action Item – Annual Review of Otic Antibiotics – See Appendix H.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**

12. **Future Business**
 - A. Annual Review of Antipsychotics
 - B. Utilization of Select Biological Agents
 - C. Utilization Review of Multiple Sclerosis Agents
 - D. New Product Reviews

13. **Adjournment**